Pro-Dex, Inc. (NASDAQ:PDEX) Shares Sold by LSV Asset Management

LSV Asset Management trimmed its position in Pro-Dex, Inc. (NASDAQ:PDEX - Free Report) by 22.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,601 shares of the medical instruments supplier's stock after selling 5,181 shares during the quarter. LSV Asset Management owned about 0.54% of Pro-Dex worth $823,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of PDEX. FMR LLC raised its position in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock worth $119,000 after buying an additional 1,028 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Pro-Dex by 9.1% in the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier's stock worth $819,000 after acquiring an additional 2,296 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Pro-Dex by 2.2% during the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier's stock worth $740,000 after purchasing an additional 529 shares during the last quarter. Ritholtz Wealth Management purchased a new position in shares of Pro-Dex during the fourth quarter worth $572,000. Finally, Bank of New York Mellon Corp acquired a new position in Pro-Dex during the fourth quarter valued at $202,000. Institutional investors and hedge funds own 15.28% of the company's stock.

Analyst Ratings Changes

Separately, StockNews.com lowered Pro-Dex from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th.

Pro-Dex Stock Performance

Pro-Dex stock traded down $0.50 during mid-day trading on Friday, hitting $60.83. The company had a trading volume of 31,110 shares, compared to its average volume of 24,856. The company has a market capitalization of $198.37 million, a price-to-earnings ratio of 30.26 and a beta of 0.40. Pro-Dex, Inc. has a 12-month low of $16.84 and a 12-month high of $65.87. The company's fifty day moving average is $46.39 and its 200-day moving average is $43.46. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. Equities research analysts predict that Pro-Dex, Inc. will post 2 EPS for the current year.

Insider Activity

In other news, Director Raymond E. Cabillot sold 842 shares of the company's stock in a transaction that occurred on Friday, March 28th. The stock was sold at an average price of $50.00, for a total transaction of $42,100.00. Following the completion of the transaction, the director now directly owns 278,945 shares of the company's stock, valued at $13,947,250. This represents a 0.30 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 35,630 shares of company stock worth $1,653,248 in the last ninety days. Company insiders own 47.50% of the company's stock.

Pro-Dex Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.